Allena Pharmaceuticals, Inc. (ALNAQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Allena Pharmaceuticals, Inc. (ALNAQ) trades at $0.00 with AI Score 44/100 (Grade C). Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Market cap: $122, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for ALNAQ: ALNAQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALNAQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALNAQ: the 1 perspectives are evenly split.
How is this calculated? →Allena Pharmaceuticals, Inc. (ALNAQ) Healthcare & Pipeline Overview
Allena Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in oral enzyme therapies for rare metabolic and kidney conditions, including its lead candidate ALLN-346 for hyperuricemia and gout. Currently under Chapter 11 reorganization, the company navigates a challenging financial landscape within the competitive biotechnology sector.
What Is the Investment Thesis for ALNAQ?
Investing in Allena Pharmaceuticals, Inc. (ALNAQ) presents significant risks due to its Chapter 11 reorganization filing in September 2022. The company's future hinges on its ability to restructure its finances and operations. The primary value driver is ALLN-346, a novel urate-degrading enzyme for hyperuricemia and gout in advanced chronic kidney disease. However, the success of ALLN-346 is uncertain, and the company's financial instability poses a major hurdle. Potential catalysts include successful restructuring and positive clinical trial updates, though these are highly speculative. Investors should carefully consider the high-risk nature of this investment, given the company's financial condition and the inherent uncertainties in pharmaceutical development. The negative beta of -14.54 indicates high volatility relative to the market.
Based on FMP financials and quantitative analysis
ALNAQ Key Highlights
- Allena Pharmaceuticals filed for Chapter 11 reorganization on September 2, 2022, impacting its operational and financial stability.
- The company's lead product candidate, ALLN-346, targets hyperuricemia and gout in patients with advanced chronic kidney disease.
- Allena Pharmaceuticals has a market capitalization of 122, reflecting its distressed financial situation.
- The company's P/E ratio is -0.07, indicating negative earnings.
- Allena Pharmaceuticals does not offer a dividend, reflecting its focus on research and development and current financial constraints.
Who Are ALNAQ's Competitors?
ALNAQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALNAQ's Key Strengths?
- Novel enzyme therapeutics for unmet needs.
- Lead product candidate ALLN-346.
- Focus on rare and severe diseases.
- Potential for orphan drug designation.
What Are ALNAQ's Weaknesses?
- Chapter 11 reorganization.
- Limited financial resources.
- Dependence on a single product candidate.
- High regulatory and clinical trial risks.
What Could Drive ALNAQ Stock Higher?
- Chapter 11 reorganization process and potential restructuring.
- Potential for securing new funding or investment.
- Clinical trial updates for ALLN-346 (timeline uncertain).
What Are the Key Risks for ALNAQ?
- Financial-distress signal — its Altman Z-Score of -28.43 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Chapter 11 bankruptcy and potential liquidation.
- Failure to secure funding and investment.
- Clinical trial failures and regulatory hurdles.
- Competition from other pharmaceutical companies.
- Limited financial resources and operational constraints.
What Are the Growth Opportunities for ALNAQ?
- Advancement of ALLN-346: Successful completion of clinical trials and regulatory approval for ALLN-346 could provide significant revenue potential, addressing the unmet needs of patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The market for gout treatments is projected to reach billions of dollars, offering a substantial opportunity if ALLN-346 demonstrates superior efficacy and safety. Timeline for approval is uncertain due to the company's financial situation.
- Expansion of Pipeline: Developing additional oral enzyme therapeutics for other rare and severe metabolic and kidney disorders could diversify Allena's product portfolio and reduce reliance on ALLN-346. Identifying new targets and advancing novel therapies through preclinical and clinical development could create long-term value. However, this depends on securing additional funding and resources, which is challenging given the current financial constraints. The timeline for new pipeline development is highly uncertain.
- Strategic Partnerships: Collaborating with larger pharmaceutical companies or research institutions could provide access to funding, expertise, and resources to accelerate the development and commercialization of Allena's products. Strategic partnerships could also expand the company's reach and market access. However, attracting partners may be difficult given the company's Chapter 11 status. The timeline for securing partnerships is uncertain.
- Restructuring and Recapitalization: Successful completion of the Chapter 11 reorganization process could provide Allena with a fresh start and the opportunity to restructure its finances and operations. Securing new funding or investment could enable the company to continue its development programs and pursue its strategic goals. The timeline for restructuring is dependent on the bankruptcy court and the company's ability to negotiate with creditors.
- Orphan Drug Designation: Obtaining orphan drug designation for ALLN-346 or other pipeline candidates could provide regulatory and financial incentives, such as market exclusivity and tax credits. Orphan drug designation can also facilitate the regulatory approval process and increase the commercial attractiveness of the product. The timeline for obtaining orphan drug designation depends on the specific regulatory requirements and the submission of a complete application.
What Opportunities Does ALNAQ Have?
- Strategic partnerships and collaborations.
- Expansion of pipeline with new enzyme therapeutics.
- Successful restructuring and recapitalization.
- Growing market for treatments for metabolic and kidney disorders.
What Threats Does ALNAQ Face?
- Competition from other pharmaceutical companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Inability to secure funding and investment.
What Are ALNAQ's Competitive Advantages?
- Patented enzyme therapeutics provide exclusivity.
- Focus on rare diseases creates niche market opportunities.
- Specialized expertise in enzyme engineering and development.
- Orphan drug designation provides market exclusivity and incentives.
What Does ALNAQ Do?
Allena Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Newton, Massachusetts. The company is dedicated to the discovery, development, and commercialization of oral enzyme therapeutics designed to treat patients suffering from rare and severe metabolic and kidney disorders. Its primary focus has been on addressing unmet needs in these therapeutic areas through innovative enzyme-based solutions. The company's lead product candidate, ALLN-346, is a novel urate-degrading enzyme intended for patients with hyperuricemia and gout, particularly in the setting of advanced chronic kidney disease. This therapy aims to reduce uric acid levels, thereby alleviating the symptoms and complications associated with these conditions. Allena Pharmaceuticals has sought to advance ALLN-346 through clinical trials, with the goal of demonstrating its safety and efficacy for potential regulatory approval and commercialization. However, on September 2, 2022, Allena Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. This event has significantly impacted the company's operations and future prospects, introducing substantial uncertainty regarding its ability to continue development programs and ultimately bring its products to market. The company's future hinges on the successful navigation of the bankruptcy process and the potential for restructuring or acquisition.
What Products and Services Does ALNAQ Offer?
- Discovers oral enzyme therapeutics.
- Develops treatments for rare and severe metabolic disorders.
- Develops treatments for rare and severe kidney disorders.
- Commercializes oral enzyme therapeutics.
- Focuses on unmet needs in specific therapeutic areas.
- Lead product candidate is ALLN-346 for hyperuricemia and gout.
How Does ALNAQ Make Money?
- Develops and patents novel enzyme therapeutics.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Commercializes approved products through partnerships or direct sales.
What Industry Does ALNAQ Operate In?
Allena Pharmaceuticals operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The market for treatments for metabolic and kidney disorders is substantial, driven by the increasing prevalence of conditions such as hyperuricemia, gout, and chronic kidney disease. However, the industry is also highly competitive, with numerous companies developing novel therapies for these indications. Allena's Chapter 11 filing reflects the challenges faced by smaller biotech companies in securing funding and navigating the complex regulatory landscape.
Who Are ALNAQ's Key Customers?
- Patients with rare and severe metabolic disorders.
- Patients with rare and severe kidney disorders.
- Healthcare providers who treat these patients.
- Pharmacies and hospitals that dispense the company's products.
F-Score 1/9Financial Health
Allena Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.43 places it in the distress zone, a signal of elevated financial risk.
ALNAQ Valuation & Market Position
With a 122 market cap, Allena Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ALNAQ's quantitative score of 44/100 is below the peer average of 76/100.
Key Financial Metrics
Return on assets is -96.0%, showing how much profit it generates from its asset base. A current ratio of 2.11 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Allena Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newton, US. ALNAQ has traded publicly since 2017.
ALNAQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel enzyme therapeutics for unmet needs.
- Lead product candidate ALLN-346.
- Focus on rare and severe diseases.
- Potential for orphan drug designation.
Bear Case
- Chapter 11 reorganization.
- Limited financial resources.
- Dependence on a single product candidate.
- High regulatory and clinical trial risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ALNAQ Latest News
No recent news available for ALNAQ.
ALNAQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALNAQ.
Price Targets
Wall Street price target analysis for ALNAQ.
ALNAQ MoonshotScore
What does this score mean?
The MoonshotScore rates ALNAQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
ALNAQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Allena Pharmaceuticals may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of fraud or mismanagement.
- Low trading volume and wide bid-ask spreads can lead to significant price volatility.
- OTC Other tier companies may not be subject to the same regulatory oversight as companies listed on major exchanges.
- The company's Chapter 11 bankruptcy adds further uncertainty and risk to the investment.
- Delisting from the OTC market is a potential risk, which could further reduce liquidity and value.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Understand the terms of the Chapter 11 reorganization plan.
- Consult with a financial advisor before investing.
- Company was incorporated in 2011.
- Focus on developing treatments for unmet medical needs.
- Lead product candidate ALLN-346 has potential in treating hyperuricemia and gout.
- Headquartered in Newton, Massachusetts.
Allena Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does Allena Pharmaceuticals, Inc. do?
Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Its lead product candidate, ALLN-346, is a novel urate-degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. However, the company filed for Chapter 11 reorganization in 2022, impacting its operations and future prospects. The company's future depends on successful restructuring.
What do analysts say about ALNAQ stock?
Given Allena Pharmaceuticals' Chapter 11 reorganization and OTC listing, formal analyst coverage is likely limited or non-existent. Key valuation metrics such as price targets and ratings are unavailable. Investment considerations revolve around the potential for successful restructuring, the future of ALLN-346, and the inherent risks associated with distressed companies. Investors should conduct their own due diligence and consider the high-risk nature of this investment. There is no analyst consensus available.
What are the main risks for ALNAQ?
The primary risk for Allena Pharmaceuticals is its Chapter 11 bankruptcy, which could lead to liquidation or significant dilution for existing shareholders. Financial instability, limited resources, and dependence on a single product candidate (ALLN-346) also pose substantial risks. Clinical trial failures, regulatory hurdles, and competition from other pharmaceutical companies further compound the challenges. Investing in ALNAQ carries a high degree of uncertainty and potential for loss.
What are the key factors to evaluate for ALNAQ?
Allena Pharmaceuticals, Inc. (ALNAQ) holds an AI score of 44/100 (low). Not financial advice.
How frequently does ALNAQ data refresh on this page?
ALNAQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALNAQ's recent stock price performance?
Allena Pharmaceuticals, Inc. (ALNAQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel enzyme therapeutics for unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALNAQ overvalued or undervalued right now?
Valuing Allena Pharmaceuticals, Inc. (ALNAQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ALNAQ?
Before investing in Allena Pharmaceuticals, Inc. (ALNAQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be limited due to the company's Chapter 11 status.
- Financial data may not be current or accurate.
- AI analysis pending for ALNAQ.